

Curriculum vitae

Name Sanjay Kulkarni, MD

Appointment: Associate Professor of Surgery
Secondary Appointment in Medicine

School Yale University School of Medicine

Education, Career, Board Certifications

Education

08/1986-05/1990 Bachelors of Science, BS
Majors: Biochemistry and Molecular Biology
University of Wisconsin-Madison, Madison, WI

08/1990-06/1995 Medical Doctorate, MD
Medical College of Wisconsin, Milwaukee, WI

07/2002-06/2004 Clinical Research Training Program
Department of Health Studies
Pritzker School of Medicine
University of Chicago, Chicago, IL

06/2014-06/2015 Global Clinical Research Scholars Training Program
Harvard Medical School
Boston, MA

07/2016-ongoing Masters in Healthcare Management Program
Harvard School of Public Health
Boston, MA

Academic/Career Positions

06/1995-06/2002 General Surgery Resident
Department of Surgery
University of Chicago Hospitals, Chicago, IL

06/2001-06/2002 Administrative Chief Surgical Resident
Department of Surgery

	University of Chicago Hospitals, Chicago, IL
01/2004-03/2004	Visiting Transplant Surgery Fellow Section of Abdominal Transplantation University Hospital-Essen, Germany
07/2002-06/2004	Transplant Surgery Fellow Department of Surgery, Section of Transplantation University of Chicago Hospitals, Chicago, IL
07/2002-06/2004	Clinical Instructor Department of Surgery, Section of Transplantation University of Chicago Hospitals, Chicago, IL
07/2004-06/2011	Assistant Professor of Surgery Yale University School of Medicine New Haven, CT
07/2008-present	Consultant Physician Greenwich Hospital Greenwich, CT
09/2012-present	Consultant Physician St. Francis Hospital Hartford, CT
07/2011-present	Associate Professor of Surgery & Medicine Yale University School of Medicine New Haven, CT

Administrative Positions

1. Director Kidney Transplant & Pancreas Transplant
Department of Surgery, Yale University School of Medicine
New Haven, CT (8/2006-present)
 - a. 2010 Healthgrades Award of Excellence. Third best kidney transplant outcomes in the United States.
 - b. 2009-2012 Region 1: Largest kidney transplant volume, largest number of new listings, and largest living donor program.
 - c. Organized first kidney paired exchange in CT. 10/2012.
2. UNOS living donor committee (2013-2015)
Chair, living donor data subcommittee (2014-2015)

3. Scientific director, Yale Transplant Research Unit (2014-present)
4. Medical director, The Center for Living Organ Donors (2016-present)

Board Certification

1. American Board of Surgery (#48019), 4/2003
2. American Board of Surgery Recertification 2012-2022
3. National Board of Medical Examiners, 12/1997

Professional Honors & Recognition

1. Fellow of the American College of Surgeons, 2007-present
2. Gift of Life, Record Achievement Award, Yale-New Haven Hospital, 2008
3. Castle Connolly Best Surgeons in Northeast, 2015

Professional Societies

1. American Society of Transplant Surgeons
2. American Hepatico-Pancreatic-Biliary Association
3. Association of Academic Surgeons
4. Transplantation Society
5. American Association for the Study of Liver Diseases
6. Vascular Biology & Therapeutics Program (Yale)
7. Human Translational Research Program (Yale)

Grant History/Investigator-Initiated Sponsored Research (Active)

1. Randomized Controlled Trial of Reducing Operative & Post-Operative Morbidity in Living Kidney Donors Utilizing Low Pressure, Limited Variability Pneumoperitoneum.

Role: Principal Investigator

Effort: 10%

Dates: 2014-ongoing

Total Direct Costs: \$68,600

Total Indirect Costs: \$29,400

Status: Enrollment Closed-Analysis
Sponsor: Surgiquest, Inc.

3. Burden of Illness in Highly Sensitized ESRD Patients & Patients Who Experience Acute Antibody-Mediated Rejection.

Role: Principal Investigator
Effort: 10%
Dates: 2014-ongoing
Total Direct Costs: \$134,525
Total Indirect Costs: \$31,044
Status: Active
Sponsor: Alexion Pharmaceuticals

4. Balancing Non-Maleficence and Autonomy: Establishing Ethical Risk Thresholds for Living Kidney Donors.

Role: Principal Investigator
Effort: 5%
Dates: 2015-present
Total Direct Costs: \$97,300
Total Indirect Costs: \$41,000
Status: Open-No cost Extension
Sponsor: The Greenwall Foundation

5. Randomized Controlled Trial of Infliximab Induction Therapy for Deceased Donor Kidney Transplant Recipients.

Role: Co-Investigator
Effort: 5%
Dates: 2015-ongoing
Total Direct Costs: \$88,235
Total Indirect Costs: \$43,252
Status: Enrolling
Sponsor: NIH/NIAID

Grant History/Investigator-Initiated Sponsored Research (Completed)

1. Inhibition of Complement in Chronic Allograft Injury & its affect on Circulating Endothelial Cells. Investigator initiated study to assess if complement inhibition can ameliorate injury in chronic allograft nephropathy associated with donor specific antibody and how this inhibition affects circulating endothelial cell activation.

Role: Principal Investigator

Effort: %15
Dates: 2011-present
Total Direct Costs: \$765,467
Total Indirect Costs:\$229,640
Status: Enrollment Closed-Analysis Phase
Sponsor: Alexion Pharmaceuticals

Clinical Trials (Active)

1. Evaluation of Benefits and Risks in Maintenance Renal Transplant Recipient Following conversion to Belatacept-Based Immunosuppression IM103-11.

Role: Principal Investigator
Dates: 2014-present
Effort: 1%
Total Direct Costs: \$163,082
Total Indirect Costs: \$48,924.60
Status: Active Enrollment
Sponsor: Bristol-Meyers Squib

2. Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation.

Role: Principal Investigator (Site)
Dates: 2014-present
Effort: 2.5%
Total Direct Costs: \$49,115
Total Indirect Costs: \$14,734
Status: Active Enrollment
Sponsor: Alexion Pharmaceuticals

Clinical Trials (Completed)

1.Sirolimus 316- A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients.

Role: Principal Investigator
Effort: 2%
Dates:6/19/2002-2/5/2009
Total Direct Costs: \$162,832
Total Indirect Costs:\$48,850
Status: Closed

Sponsor: Wyeth Pharmaceuticals

2.ORION- A Randomized Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients

Role: Principal Investigator
Effort: 2%
Dates:2/2/2005-5/21/2008
Total Direct Costs: \$117,400
Total Indirect Costs:\$35,220
Status: Closed
Sponsor: Wyeth Pharmaceuticals

3.Myfortic: A three-month, open-label, two cohort study to investigate the safety and tolerability of Myfortic® in combination with Neoral® or Tacrolimus in renal transplant recipients with GI intolerance (My TIME)

Role: Principal Investigator
Effort: 2%
Dates:9/28/2007-1/22/2009
Total Direct Costs: \$46,120
Total Indirect Costs: \$13,836
Status: Closed
Sponsor: Novartis Pharmaceuticals

4.CP-690,550: A phase 2 randomized, multicenter, active comparator-controlled trial to evaluate the safety and efficacy of coadministration of CP-690,550 and mycophenolate mofetil/mycophenolate sodium in de novo kidney allograft recipients.

Role: Principal Investigator
Effort: 2%
Dates: 10/29/2007 to 2010
Total Direct Costs: \$78,812
Total Indirect Costs: \$23,644
Status: Closed
Sponsor: Pfizer Pharmaceuticals

5.CP-690,550 Extension: A phase 2, multicenter, open-label, active comparator-controlled, extension trial to evaluate the long-term safety and efficacy of CP-690,550 in renal allograft recipients.

Role: Principal Investigator
Effort: 2%

Dates: 11/21/2008 to present
Total Direct Costs: \$67,771
Total Indirect Costs:\$20,331
Status: Data Management
Sponsor: Pfizer Pharmaceuticals

6.LCP-Tacro: A phase 3, open-label, multicenter, prospective, randomized study to determine the efficacy and safety of conversion of Prograf capsules twice daily to LCP-Tacro tablets once daily for the prevention of acute allograft rejection in stable kidney transplant patients.

Role: Principal Investigator
Effort: 12%
Dates: 2/4/2009 to 2012
Total Direct Costs: \$131,610
Total Indirect Costs:\$39,483
Status: Closed
Sponsor: Life Cycle Pharmaceuticals

7. Noninvasive Markers & Transplantation Outcomes in Humans: Clinical monitoring trial to assess the efficacy of biomarkers in predicting long-term kidney graft function.

Role: Co-investigator
Effort: 1%
Dates:9/01/2004 to 2011
Status: Closed
Sponsor: AI/NIAID/NHLBI 1-u-1-AI063594-01

8. A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP Tacro Tablets, Once Daily, Compared to Prograf Capsules, Twice Daily, in Combination with Mycophenolate Mofetial for the precention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients.

Role: Principal Investigator
Effort: 1%
Total Direct Costs: \$129,924 Total Indirect Costs:\$38,977
Sponsor: Veloxis Pharmaceuticals

Invited Speaking Engagements, Presentation, Symposia & Workshops

International/National

1. Who Should Decide? Potential Living Kidney Donor Preferences for Making Decisions About Risk (Thiessen C/Kulkarni S). *American Transplant Congress*. 11-15 June 2016. Boston, MA.
2. Financial Burdens and Coping Mechanisms of Living Kidney Donors (Li S/Kulkarni S). *American Transplant Congress*. 11-15 June 2016. Boston, MA.
3. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance (Thiessen C/Kulkarni S). *European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT)*. 22-25 April 2016, Rome, Italy.
4. Balancing Non-Maleficence and Autonomy: A Donor-Centered Approach to Risk Assessment (Kulkarni S). *European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT)*. 22-25 April 2016, Rome, Italy.
5. Low-Pressure Laparoscopic Donor Nephrectomy is Associated with Improved Donor and Recipient Outcomes (Kulkarni S). *American Surgical Congress*. 2-4 February 2016. Jacksonville, FL.
6. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance (Thiessen C/Kulkarni S). *American Surgical Congress*. 2-4 February 2016. Jacksonville, FL.
7. Living Kidney Donor Risk Preferences: Quantifying Risk Acceptance Using a Novel Decision-making Aid (Gannon J/ Kulkarni S) *American Society for Bioethics & the Humanities*. 22-25 October 2015, Houston, TX.
8. Implementation of a Donor-Centered Approach to Living Kidney Donor Evaluation: Challenges and Opportunities for Transplant Centers (Kulkarni S/ Reese P). *American Society for Bioethics & the Humanities*. 22-25 October 2015, Houston, TX.
9. A Donor-Centered Approach to Risk Assessment: Normative Considerations for and Against Shared Decision Making in Living Kidney Donor Evaluation (Gordan E/Kulkarni S). *American Society for Bioethics & the Humanities*. 22-25 October 2015, Houston, TX.

10. Shared Decision-making During the Living Kidney Donor Evaluation Process: Results of a Prospective Qualitative Study (Thiessen C/Kulkarni S). *American Society for Bioethics & the Humanities*. 22-25 October 2015, Houston, TX.
11. "I Can't Become Homeless in Order to Help My Daughter": Reasons for and the Psychosocial Impact of Opting Out of Living Kidney Donation (Jaji Z/Kulkarni S). *American Society for Bioethics & the Humanities*. 22-25 October 2015, Houston, TX.
12. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation (Thiessen C/Kulkarni S). *American Psychosomatic Medicine 2014 Annual Meeting*. Ft. Lauderdale, FL. 12-15 November 2014.
13. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation (Thiessen C/Kulkarni S). *European Association of Psychosomatic Medicine 2015*. Nuremberg, Germany. 2-4 July 2015.
14. Eculizumab therapy for chronic antibody mediated rejection: A preliminary assessment (Kulkarni S/Pober J) *World Transplant Congress*, June 2014. San Francisco, CA.
15. Living kidney donor risks and benefits: A review of evaluation consent forms. Presented as part of the panel "Protecting Living Kidney Donors: Empirical and Normative Advances" (Thiessen C/Kulkarni S). *American Society for Bioethics and the Humanities 2014 Annual Meeting*. 16-19 October 2014. San Diego, CA.
16. Eculizumab therapy for chronic antibody mediated rejection: A preliminary assessment (Kulkarni S/Pober J) *American Transplant Congress*. Seattle, WA. May 2013.
17. Opting Out: Confidentiality & Alibis for Living Kidney Donors (Thiessen C/Kulkarni S). *American Transplant Congress*. Seattle, WA. May 2013.
18. Living Kidney Donor Consent: Compliance with CMS & OPTN Requirements. Concurrent Session 43: Regulation & Donation (Thiessen C/Kulkarni S). *American Transplant Congress*. Seattle, WA. May 2013.
19. Opting Out: Confidentiality & Alibis for Living Kidney Donor (Thiessen C/Kulkarni S). *American Society for Bioethics and the Humanities*. Atlanta, GA. October 2013.

20. Workshop on essential elements of donor and recipient evaluations. *World Transplant Congress* (Kulkarni S/Moore D) June 2013. Seattle, WA.
21. A QI Initiative and Improves Access to Kidney Transplantation (Kulkarni S) *Transplant Grand Rounds, University of Cincinnati*. December 11, 2012.
22. Complication Management following kidney transplantation (Kulkarni S) *Sanatorio Allende Hospital*, October 13, 2011, Cordoba, Argentina.
23. Center Coordinated, Pre-Transplant Evaluation Eliminates Barriers to Kidney Transplantation & Establishes Parity Across Socio-economic Groups (Kulkarni S) *Ochsner Clinic Grand Rounds*, November 11, 2010. New Orleans, LA.
24. Center Coordinated, Pre-Transplant Evaluation Eliminates Barriers to Kidney Transplantation & Establishes Parity Across Socio-economic Groups (Kulkarni S/Formica R) *The International Congress of the Transplantation Society*. August 17, 2010. Vancouver, BCI.

Regional

1. Pancreas Transplantation: Balancing glycemic control with surgical morbidity Medical Grand Rounds. February 4, 2011. *Hartford Hospital*, Hartford, CT.
2. Utilization of Marginal Organs for Transplantation. September 6, 2010. *New England Organ Bank Symposium*. September 2010, Wooster, MA

Peer-Reviewed Poster Presentations

International/National

1. Eculizumab Therapy for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients: A Randomized-Controlled Trial (Kulkarni S/ Pober J) *American Transplant Congress*. 11-15, June 2016. *Awarded Poster of Distinction*.
2. Low-Pressure Pneumoperitoneum in Living Kidney Donors: A Randomized-Controlled Trial (Kulkarni S/ Hall I) *American Transplant Congress*. 11-15, June 2016.
3. Attitudes Toward Living Kidney Transplantation Among Potential Transplant Recipients (Yu K/Kulkarni S) *American Transplant Congress*. 11-15, June 2016.

4. Opting Out: A Pilot Study Assessing the Reasons for and the Psychosocial Impact of Withdrawing from Living Kidney Donor Evaluation (Thiessen C/Kulkarni S) *European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT)*. 22-25 April 2016, Rome, Italy.
5. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance (Dobosz D/Kulkarni S) *American Transplant Congress*. 11-15, June 2016.
6. Living Kidney Donor Risk Preferences: Quantifying Risk Acceptance Using a Novel Decision-Making Aid. American Society of Transplant Surgeons Winter Symposium (Thiessen C/Kulkarni S) Miami, FL. 14-17 January 2016. *Awarded Poster of Distinction*.
7. Burden of Disease in Kidney Transplant Recipients with Low Immunologic Risk Antibody-Mediated Rejection (Kulkarni S/Hall I) *American Transplant Congress*. 2-6, May 2015.
8. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation (Thiessen C/Kulkarni S) *World Transplant Congress*. San Francisco CA. 26-31 July 2014.
9. Informed consent for living liver donation: compliance with CMS & OPTN requirements and alibi offers (Thiessen C/Kulkarni S) *Joint International Congress of ILTS, ELITA & LICAGE*. London, United Kingdom. 4-7 June 2014.

Professional Service

Peer Review Groups/Grant Study Sections

1. Grant Reviewer: *PSI (Physician Services Incorporated) Foundation* 2014.
2. Grant Reviewer: *ASTS Collaborative Scientist Award* 2014.
3. Grant Study Section: Clinical Trials Award, *American Institute of Biological Sciences (US Army Medical Research & Material Command, DOD)* 2012.

Advisory Boards

1. Medical Advisory Board, *American Kidney Foundation*, 2012-2013.

2. Scientific Advisory Board, *Alexion Pharmaceuticals*, 15, November 2011.
3. Medical Guidelines Consensus Board, *KDOQI*, 23 October 2009.
4. Kidney/Pancreas Advisory Board, UNOS Region 1, 2007-2013.

Journal Service

Editorial Board

Hepatology, 2013-ongoing

Reviewer

1. American Journal of Transplantation (Frequent)
2. Transplantation (Frequent)
3. Clinical Transplantation
4. Hepatology
5. New England Journal of Medicine
6. Journal of the American College of Surgeons
7. Annals of Surgical Oncology
8. Connecticut Medicine
9. Clinics and Research in Hepatology & Gastroenterology
10. Journal of Medical Ethics

Professional Service for Professional Organizations

1. Program Committee, *American Association for the Study of Liver Diseases*, 2013-2015.
2. Session Chair, *American Transplant Congress*, May 2008.

Yale University Services

Medical School/Department Committees

1. Yale Medical School Faculty Advisory Council, 2015-ongoing

2. Member, Steering Committee, *Human Translational Immunology Program*, 2013-ongoing
3. Member, Appointment & Promotions Committee, Department of Surgery, 2012-ongoing

Hospital Boards & Committees

4. Development of “The Center for Living Donation”, 2015
5. Blood Utilization Committee, Yale-New Haven Hospital, 2011-2014
6. Laboratory Utilization Review Committee, 2012-2013
7. Chair, Kidney & Pancreas Medical Review Board 2007-present

Bibliography

Peer-Reviewed Original Research

1. O’Herrin S, **Kulkarni S**, Kenealy W, Fechner J, Sollinger HW, Scheck J and Burlingham WJ. Expression of human recombinant b2 microglobulin by *Aspergillus nidulans* and its activity. *Human Immunology* 1996;51:63.
2. **Kulkarni S**, Holman P, Kopelan A, van Seventer G, van Seventer J, Kranz D and Woodle ES. Programmed cell death signaling via membrane expression of a single-chain antibody transgene. *Transplantation* 2000;127;318-322.
3. **Kulkarni S**, Naureckas E and Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. *Transplantation* 2003;75(6):899-901.
4. Schaffer RL, **Kulkarni S**, Harper A, Millis JM and Cronin DC. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region’s experience. *Liver Transplantation* 2003; 9(11):1211-5.
5. **Kulkarni S** and Cronin, DC. Ethical tensions in solid organ transplantation: The price of success. *World J Gastroenterol* 2006;12(20): 3259-3264.
6. **Kulkarni S** and Cronin DC. Ethics in Liver Transplantation. *Seminars in Liver Disease* 2006;26(3):234-238.

7. Friedman AL, Geoghean SR, Sowers NM, **Kulkarni S**, and Formica RN. Medication errors in the outpatient setting: classification and root cause analysis. *Archives of Surgery* 2007;142(3):278-283.
8. Parekh AM, Gordon EJ, Garg AX, Waterman AD, **Kulkarni S**, Parikh CR. Living donor informed consent practices vary between US and non-US centers. *Nephrol Dial Transplant* 2008;23(10):3316-3324.
9. Formica R, Asch W, Wagner K and **Kulkarni S**. HIV Disclosure in Living Donor Kidney Transplantation. *Clinical Journal of American Society of Nephrology* 2010; March 4.
10. **Kulkarni S**, Emre S, Arvelakis A, Bia M, Asch W, Formica and Isreal G. Multidetector CT Angiography in Living Donor Kidney Transplantation: Accuracy and Discrepancies in Right Venous Anatomy. *Clinical Transplantation* 2010;25(1):77-82.
11. Caldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, **Kulkarni S** and Emre S. Use of Model for End-Stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with review of the literature. *Liver Transplantation* 2010; March 16.
12. Bia M, Adey BA, Bloom RD, Chan L, **Kulkarni S** and Tomlanovich S. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *American Journal of Kidney Disease* 2010;56(2):189-218.
13. Solomon DA, Rabidou N, **Kulkarni S**, Formica R and Fraenkel L. *Clinical Transplantation* 2010 Oct 22.
14. Tobiasova Z, Lufeng Z, Tai Y, Linfeng Q, **Kulkarni S**, Lorber M, Rodriguez F, Choi J, Tellides F, Pober J, Kawikova I and Bothwell A. PPAR γ agonists prevent *in vivo* remodeling of human artery induces by alloreactive T cells. *Circulation* 2011;124(2):196-205.
15. Fogal B, Yi T, Wang C, Rao DA, Lebastchi A, **Kulkarni S**, Tellides G, and Pober JS. Neutralizing IL- γ reduces human arterial allograft rejection by allowing emergence of CD161(+) CD4(+) regulatory T cells. *Journal of Immunology* 2011;187(12):6268-6280.
16. Yi T, Fogal B, Hao Z, Tobiasova Z, Wang C, Rao DA, Al-Lamki RS, Kirkiles-Smith NC, **Kulkarni S**, Bradley JR, Bothwell AL, Sessa WC, Tellides G, and Pober JS. Reperfusion injury intensifies the adaptive

- human T cell alloresponse in a human-mouse chimeric artery model. *Arterioscler Thromb Vasc Biol* 2012;32(2):353-360.
17. Fromica RN, Barrantes F, Asch WS, Bia M, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Stint K and **Kulkarni S**. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. *American Journal of Kidney Disease* 2012;60(2):288-294.
 18. Fromica RN, Barrantes F, Asch WS, Bia M, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Stint K and **Kulkarni S**. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. *American Journal of Kidney Disease* 2012;60(2):288-294.
 19. Guo X, Schmitz JC, Kenney BC, Uchio EM, **Kulkarni S** and Cha C. Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survival. *Cancer Science* 2012;103(8):1474-1480.
 20. Heavner M, Tichy E, Yazdi M, Formica R, **Kulkarni S**, and Emre S. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. *Am J Health-Syst Pharm*. 2013;70:1507-1512.
 21. Gandelman J, Yoo P and **Kulkarni S**. Retrocaval arterial bifurcation is not a contraindication to laparoscopic right donor nephrectomy. *Journal of the American College of Surgeons* 2013;217(3):406-411.
 22. Davarpanah AH, Pahade JK, Cornfield D, Gita M, **Kulkarni S**, and Isreal GM. CT angiography in potential living kidney donors: 80 kVp versus 120 kVp. *AJR American Journal of Roentgenology* 2013;201(5):W753-W760.
 23. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, Abrahimi P, Devalliere J, Moeckel G, **Kulkarni S**, Tellides G, and Pober JS. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through non-canonical NK-kB signaling in endothelial cells. *Circulation* 2013;128(23):2504-2516.
 24. Thiessen C, Kim YA, Formica R, Bia M and **Kulkarni S**. Written informed consent for living kidney donors: Practices and compliance with CMS and OPTN Requirements. *American Journal of Transplantation* 2013;13(10):2713-2721.
 25. Rodriguez M, Arvelakis A, Umman V, Tanjavur V, Yoo P, **Kulkarni S**, Lucyzski S, Shilsky M and Emre S. Segmental grafts in adult and pediatric

- liver transplantation: improving outcomes by minimizing vascular complications. *JAMA Surgery* 2014;149(1):63-70.
26. Thiessen C, Kim YA, Yoo PS, Rodriguez-Davalos M, Mulligan D and **Kulkarni S**. Written informed consent for living liver donor evaluation: Compliance with CMS & OPTN guidelines and alibi offers. *Liver Transplantation* 2014;20(4):416-424.
 27. Viarinho S, Choi M, Jain D, Malhotra A, **Kulkarni S**, Pashankar D, Phatak U, Patel M, Bale A, Mane S, Lifton RP, Mistry PK. Individual exome analysis in diagnosis and management of pediatric liver failure of indeterminate etiology. *Journal of Hepatology* 2014;61(5):1056-1063.
 28. Thiessen C, Kim YA, Formica R, Bia M and **Kulkarni S**. Confidentiality and availability of an “alibi” for potential living kidney donors in the United States. *Journal of Medical Ethics* 2015;41(7):506-510.
 29. Thiessen C, Gordon EJ, Reese PP, **Kulkarni S**. Development of a Donor-Centered Approach to Risk Assessment: Rebalancing Non-maleficence and Autonomy. *American Journal of Transplantation* 2015;15(9):2314-2323.
 30. Guerra CM, Formica RN, **Kulkarni S**, Asch WS and Tichy EM. Duration of prophylaxis against fungal infection in kidney transplant recipients. *Progress in Transplantation* 2015;25(4):311-315.
 31. Thiessen C, **Kulkarni S**, Reese PP and Gordon EJ. A call for research on individuals who opt out of living kidney donation: Challenges and opportunities. *Transplantation* 2016, [epub ahead of print].
 32. **Kulkarni S**, Kirkles-Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R and Pober J. Eculizumab for chronic antibody-mediated rejection in kidney transplant recipients randomized-controlled trial. *American Journal of Transplantation* 2016, [epub ahead of print]
 33. **Kulkarni S**, Thiessen C, Formica R, Schilsky M, Mulligan D and D’ Aquila R. The longterm follow-up and support for living organ donors: A center-based initiative founded on developing a community of living donors. *American Journal of Transplantation* 2016, [epub ahead of print].

Reviews, Book Chapters, Case Reports

1. Woodle ES and **Kulkarni S**. Programmed Cell Death. *Transplantation* 1998;681-691.

2. **Kulkarni S**, Holman P, Kopelan A, van Seventer G, van Seventer J, Kranz D and Woodle ES. Programmed cell death signaling via membrane expression of a single-chain antibody transgene. *Transplantation*. 2000;127;318-322.
3. **Kulkarni S**, Kopelan A. and Woodle ES. Tacrolimus and Kidney Transplantation. *Kidney Transplantation 3rd Edition*, William and Wilkens.
4. **Kulkarni S** and Cronin DC. Fulminant Liver Failure. *Principles of Critical Care 3rd edition*. McGraw-Hill.
5. **Kulkarni S**, Malago, M and Cronin DC. Living donor liver transplantation for pediatric and adult recipients. *Nature: Clinical Gastroenterology and Hepatology*. 2006;3(3):149-157.
6. Licure A, **Kulkarni S**, Formica R, Ultrasonography and Clinical Management in the Renal Transplant Recipient. *US Nephrology* 2008 1-4.
7. **Kulkarni S**, Kidney Transplantation: Surgical Procedure, American Society of Transplant Surgeons, Transplant Universe Module, 2010.
8. **Kulkarni S**, Kidney Transplantation: Surgical Complications, American Society of Transplant Surgeons, Transplant Universe Module, 2010.
9. Cuffy M, Singh M, Formica R, Simmons E, Abu Alfa A, Carlson K, Girardi M, Cowper SE, and **Kulkarni S**. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. *Nephrology Dialysis & Transplantation* 2011;26(3):1099-101.
10. **Kulkarni S** and Taddei T. Should Hepatitis C patients with ESRD receive kidney transplants? *Seminars in Dialysis* 2011;24(4):438-439.
11. Tichy EM, Medwid AJ, Mills EA, Formica RN, **Kulkarni S**. Significant sirolimus and dronedarone interaction in a kidney transplant recipient. *Annals of Pharmacotherapy* 2010. May 18th.
12. Singh M, Singh G, Pandey A, Cha C and **Kulkarni S** Laparoscopic repair of iatrogenic diaphragmatic hernia following radiofrequency ablation for hepatocellular carcinoma. *Hepatology Research* 2011;41:1132-1136.
13. Christakis PG, Cimsit B, **Kulkarni S**. Complication arising from a duplicated inferior vena cava following laparoscopic living donor nephrectomy. A case report. *Transplant Proc* 2012;44(5):1450-1452.

- 14.** Yoo P and **Kulkarni S**. Anatomical considerations for the surgical resection of hepatocellular carcinoma. *J Clin Gastroenterol* 2013;47(suppl:S11-S5).

- 15.** Cohen EA, Mulligan D, **Kulkarni S** and Tichy EM. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient. *American Journal of Transplantation* 2016 (epub ahead of print)